FRE Stock Overview
A health care company, provides products and services for chronically ill patients. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Community Narratives
Create a narrativeNarratives bring a range of perspectives from our community.
Fresenius SE & Co. KGaA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €33.20 |
| 52 Week High | €36.24 |
| 52 Week Low | €24.32 |
| Beta | 1.04 |
| 1 Month Change | -0.33% |
| 3 Month Change | 0.12% |
| 1 Year Change | 16.04% |
| 3 Year Change | -5.17% |
| 5 Year Change | -33.81% |
| Change since IPO | 2,840.67% |
Recent News & Updates
Is Fresenius SE KGaA (ETR:FRE) Using Too Much Debt?
Dec 20
Getting In Cheap On Fresenius SE & Co. KGaA (ETR:FRE) Might Be Difficult
Nov 29Fresenius SE KGaA (ETR:FRE) Is Finding It Tricky To Allocate Its Capital
Sep 18Recent updates
Is Fresenius SE KGaA (ETR:FRE) Using Too Much Debt?
Dec 20Getting In Cheap On Fresenius SE & Co. KGaA (ETR:FRE) Might Be Difficult
Nov 29Fresenius SE KGaA (ETR:FRE) Is Finding It Tricky To Allocate Its Capital
Sep 18Is There Now An Opportunity In Fresenius SE & Co. KGaA (ETR:FRE)?
Sep 03Investors Still Waiting For A Pull Back In Fresenius SE & Co. KGaA (ETR:FRE)
Aug 19We Think Fresenius SE KGaA (ETR:FRE) Is Taking Some Risk With Its Debt
Jul 15Fresenius SE KGaA (ETR:FRE) Has Some Difficulty Using Its Capital Effectively
Jun 12At €29.20, Is Fresenius SE & Co. KGaA (ETR:FRE) Worth Looking At Closely?
May 28With Fresenius SE & Co. KGaA (ETR:FRE) It Looks Like You'll Get What You Pay For
May 02Does Fresenius SE KGaA (ETR:FRE) Have A Healthy Balance Sheet?
Mar 29Fresenius SE KGaA (ETR:FRE) Could Be At Risk Of Shrinking As A Company
Mar 13Why Fresenius SE & Co. KGaA (ETR:FRE) Could Be Worth Watching
Feb 06A Look At The Fair Value Of Fresenius SE & Co. KGaA (ETR:FRE)
Jan 19Fresenius SE & Co. KGaA's (ETR:FRE) Shares Not Telling The Full Story
Jan 03Shareholder Returns
| FRE | DE Healthcare | DE Market | |
|---|---|---|---|
| 7D | -4.7% | -3.5% | -2.6% |
| 1Y | 16.0% | 15.6% | 6.9% |
Return vs Industry: FRE matched the German Healthcare industry which returned 15.6% over the past year.
Return vs Market: FRE exceeded the German Market which returned 6.9% over the past year.
Price Volatility
| FRE volatility | |
|---|---|
| FRE Average Weekly Movement | 2.7% |
| Healthcare Industry Average Movement | 4.7% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.3% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: FRE has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: FRE's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 177,091 | Michael Sen | www.fresenius.com |
Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure.
Fresenius SE & Co. KGaA Fundamentals Summary
| FRE fundamental statistics | |
|---|---|
| Market cap | €18.70b |
| Earnings (TTM) | -€479.00m |
| Revenue (TTM) | €22.81b |
0.8x
P/S Ratio-39.0x
P/E RatioIs FRE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| FRE income statement (TTM) | |
|---|---|
| Revenue | €22.81b |
| Cost of Revenue | €17.48b |
| Gross Profit | €5.33b |
| Other Expenses | €5.81b |
| Earnings | -€479.00m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.85 |
| Gross Margin | 23.37% |
| Net Profit Margin | -2.10% |
| Debt/Equity Ratio | 60.9% |
How did FRE perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 00:51 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Fresenius SE & Co. KGaA is covered by 49 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Martin Schnee | AlphaValue |
| Hassan Al-Wakeel | Barclays |
| Robert Bate | Barclays |